
Erratum

Rubin RR, Peyrot M: Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies (Brief Report). *Diabetes Care* 27:2495–2497, 2004

The following duality of interest information was omitted from the above-listed article.

M.P. has served as a consultant for Medtronic MiniMed, MannKind Biopharmaceuticals, and Novo Nordisk and has received research grants from Medtronic MiniMed.